Briakinumab, CAS 339308-60-0

Product Description: Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis[1].

Applications: COVID-19-immunoregulation

Formula: N/A

References: [1]Panaccione R, et, al. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflamm Bowel Dis. 2015 Jun;21(6):1329-40. /[2]Reich K, et, al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med. 2011 Oct 27;365(17):1586-96.

CAS Number: 339308-60-0

Molecular Weight: N/A

Compound Purity: 95.00

Research Area: Inflammation/Immunology

Solubility: H2O

Target: Interleukin Related

• Artikelnummer: MEXHY-P99486-1
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99486-1
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated